Zydus Lifesciences Limited · NSE:ZYDUSLIFE
Zydus Lifesciences — Q3 FY24 Earnings Presentation
16 slides from Zydus Lifesciences's earnings presentation, Feb 9, 2024
Slide 1: Cover letter to exchanges: Investor Presentation
zyd Dedicated To Life February 9, 2024 Listing Department Code: 532321 BSE LIMITED P J Towers, Dalal Street, Mumbai–400 001 Listing Department Code: ZYDUSLIFE NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, C/1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai–400 051 Re: Investor Presenta
Slide 2: Zydus Lifesciences Limited Earnings Presentation: Q3 FY24
zyd us Dedicated To Life Zydus Lifesciences Limited Earnings Presentation: Q3 FY24 9th February, 2024 1
Slide 3: Disclaimer and Safe Harbor Statement
Disclaimer and Safe Harbor Statement zyd~ Dedicated To Life • THIS PRESENTATION (PRESENTATION) IS NOT AN OFFER TO SELL ANY SECURITIES OR A SOLICITATION TO BUY ANY SECURITIES OF ZYDUS LIFESCIENCES LIMITED OR ITS SUBSIDIARIES OR JOINT VENTURES (TOGETHER, THE “COMPANY”). The material that follows is a
Slide 4: Q3 FY24: At a Glance
Q3 FY24: At a Glance zyd~ Dedicated To Life Revenues from Highlights of Q3 FY24 R&D Operations ''' ❑ Total revenues grew 6% YoY, led by India and EM& EU formulations Rs. 45,052 mn Rs. 3,146 mn businesses. ' ''' '' '' 6% YoY '' '' 7.0% of revenues ❑ India formulations business delivered strong double
Slide 5: Key Financial Metrics (1/2)
Key Financial Metrics (1/2) zyd~ Total Revenues (Rs. mn) Gross Profit (Rs. mn) and Gross Margin % 64.5% 66.2% 67.4% 66.3% 67.4% 50,106 51,396 34,652 33,146 42,571 43,688 45,052 30,367 27,468 28,950 Q3 FY23 Q4 FY23 Q1 FY24 Q2 FY24 Q3 FY24 Q3 FY23 Q4 FY23 Q1 FY24 Q2 FY24 Q3 FY24 Total R&D (Rs. mn) and
Slide 6: Key Financial Metrics (2/2)
Key Financial Metrics (2/2) zyd~ PAT ex. Exceptional (Rs. mn) Organic Capex (Rs. mn) 11,011 8,979 2,554 8,007 7,896 2,203 2,162 2,137 2,040 6,229 Q3 FY23 Q4 FY23 Q1 FY24 Q2 FY24 Q3 FY24 Q3 FY23 Q4 FY23 Q1 FY24 Q2 FY24 Q3 FY24 Net Debt/ EBITDA Net Working Capital* (Rs. mn) 63,906 56,290 57,051 55,833
Slide 7: India Formulations business
India Formulations business zyd~ Dedicated To Life Strong volume uptake drove the growth Highlights for the quarter India Formulations Sales (Rs. mn) Q3 FY24 Revenue Contribution ▪ Branded business grew faster with 17% YoY growth. 14,273 12,896 13,341 12,316 12,270 Key pillar brands and innovation p
Slide 8: Consumer Wellness
Consumer Wellness zyd~ Dedicated To Life Category leading brands continued to gain market share Highlights for the quarter Consumer Wellness Sales (Rs. mn) Q3 FY24 Revenue Contribution 7,075 6,936 ▪ FMCG sector witnessed subdued demand similar to previous quarter as expected buoyancy in demand 4,352
Slide 9: US Formulations business
US Formulations business zyd~ Dedicated To Life Base business displayed sustained volume growth Highlights for the quarter US Formulations Sales (Rs. mn) Q3 FY24 Revenue Contribution 24,541 ▪ Profitability of base business improved on the back of 22,525 sustained volume expansion and new product 19,
Slide 10: Emerging Markets & Europe Formulations business
Emerging Markets & Europe Formulations business zyd~ Dedicated To Life All key markets continued to display strong momentum Highlights for the quarter EM & EU Formulations Sales (Rs. mn) Q3 FY24 Revenue Contribution 4,937 ▪ All major markets of Asia Pacific region and Africa 4,893 4,393 4,504 regist
Slide 11: Updates on Innovation (1/2)
Updates on Innovation (1/2) zyd~ Dedicated To Life NCE: Saroglitazar Magnesium • Expect to complete recruitment of patients for Phase II(b)/ III clinical trials for PBC indication for the US market during the current quarter. • Completed hepatic impairment studies in cirrhotic cholestatic patients a
Slide 12: Updates on Innovation (2/2)
Updates on Innovation (2/2) zyd~ Dedicated To Life Biotech R&D • The pipeline continues to advance with two mAbs awaiting marketing approvals in India. • Two other products including one mAb are currently undergoing Phase III clinical trials in India. Specialty Initiatives • Completed asset transfer
Slide 13: Zydus at a Glance
Zydus at a Glance zyd~ Dedicated To Life ~$2.15 bn Global Revenues1 5th Largest generic Co. in US in terms of prescription3 7 R&D Centers For NCE, APIs, Gx formulations, Biosimilars and Vaccines Among 1st Revenues from India Approved product for >40% In ~55% of product Geography (Formulations Top 3
Slide 14: Consolidated Financial Performance (reported)
Consolidated Financial Performance (reported) zyd~ Dedicated To Life Q3 I Q3 I YoY Q2 QoQ 9M 9M YoY Rs. mn I I FY24 I FY23 I gr. FY24 gr. FY24 FY23 gr. Total Income from Ops. 45,052 42,571 5.8% 43,688 3.1% 1,40,136 1,22,268 14.6% Gross Contribution (GC) 30,367 27,466 10.6% 28,950 4.9% 93,969 76,127
Slide 15: Details of Exchange Rate Fluctuations
Details of Exchange Rate Fluctuations zyd~ Dedicated To Life Q3 Q3 YoY 9M 9M YoY Rs. mn I FY24 FY23 gr. % FY24 FY23 gr. % A. On operating transactions (above EBITDA line) -228 -1,097 79.2% -807 -3,639 77.8% a. Included in COGS -22 -44 51% -50 -210 76.4% b. Part of other operating expenses (shown sep
Slide 16: Thank you
Thank you For any queries, please contact Arvind Bothra Arvind.Bothra@zyduslife.com +91-22-62711905 For more information, please visit: www.zyduslife.com Registered Office: www.linkedin.com/company/zyduslife Zydus Corporate Park, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi C